PHARMACY

FDA gives new approval to Bristol-Myers Squibb’s, Lilly’s Erbitux

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb and Eli Lilly & Co. for treating head and neck cancer, the agency said Monday.

The FDA announced the approval of Erbitux (cetuximab) for use with chemotherapy in treating head and neck cancer that had spread to other parts of the body. The drug originally was approved in 2004 for treating certain cases of late-stage colon cancer in patients who had stopped responding to chemotherapy.

"Erbitux’s ability to extend the lives of patients with head and neck cancers is an important tool for oncologists who often rely on a multitreatment approach for patients," FDA Office of Hematology and Oncology Drug Products director Richard Pazdur said. "Given the aggressive nature of head and neck cancers that cannot be treated with surgery and radiation, it is important for patients to have as many treatment options available as possible."

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Report: Sainsbury’s launches ‘The Wells Challenge’

BY Alaric DeArment

NEW YORK — A supermarket chain in the United Kingdom has launched a new initiative that will enlist 10 families with the same surname, according to published reports.

The Retail Gazette reported that the Sainsbury’s chain had launched "The Wells Challenge," which will assess the effects on the health of 10 families with the surname Wells as the chain’s pharmacists provide them with health-related guidance and support.

The think tank 2020health is monitoring the initiative, which is designed to reduce pressure on Britain’s National Health Service, the country’s state-run healthcare system.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA appoints new commissioner’s chief of staff

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has appointed a new chief of staff for commissioner Margaret Hamburg, according to a letter sent to agency employees Monday.

In the letter, Hamburg announced the appointment of Lisa Barclay. Barclay, currently a partner at the Washington law firm Zuckerman Spaeder, will replace Molly Muldoon, who was previously chief of staff and more recently the agency’s acting COO.

Barclay previously worked with the FDA in the 1990s, with the Commissioner’s Office of Policy, and also has worked on Capitol Hill and as a law clerk for senior judge William Bryant of the U.S. District Court for the District of Columbia.

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES